JNJ vs ORKA
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. ORKA: Oruka Therapeutics is a clinical-stage biotech developing engineered monoclonal antibodies to set a new standard of care in chronic skin diseases like psoriasis.
Side-by-side fundamentals
| Metric | JNJ | ORKA | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $270.24 | $107.96 | |
| Market cap as of 2026-08-24 | $651.3B | $7.1B | |
| P/E as of 2026-08-24 | 29.93 | n/a | |
| PEG as of 2026-08-24 | 3.39 | n/a | |
| Net margin as of 2026-08-24 | +21.5% | -26.3% | JNJ higher |
| Gross margin as of 2026-08-24 | +68.0% | n/a | |
| Operating margin as of 2026-08-24 | +25.7% | -40.3% | JNJ higher |
| ROE as of 2026-08-24 | +25.7% | -26.0% | JNJ higher |
| ROA as of 2026-08-24 | +10.6% | -25.0% | JNJ higher |
| Debt / equity as of 2026-08-24 | 0.58 | 0.00 | ORKA lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +6.2% | n/a | |
| Dividend yield as of 2026-08-24 | +3.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.20 | -0.42 | |
| 1-year return as of 2026-08-21 close | +51.0% | +630.0% | ORKA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.